Reports FY24 revenue $670,000 vs $740,000 last year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma initiates Phase 3 psoriasis study of piclidenoson
- CANF Earnings this Week: How Will it Perform?
- Can-Fite BioPharma Advances Canine Osteoarthritis Treatment with Vetbiolix Partnership
- Can-Fite BioPharma to Begin Phase II Study for Lowe Syndrome Treatment
- Can-Fite BioPharma to initiate Phase II study in Lowe Syndrome